Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 4/20 | 0.45 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | LAP3 | P28838 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5558434 | 1.00 | SLC1A3 (0.46) | SLC1A3SLC1A2MMECPA1MGAM | |
| SCHEMBL8047058 | 1.00 | SLC1A3 (0.46) | SLC1A3SLC1A2MMECPA1MGAM | |
| SCHEMBL1246334 | 0.86 | MGAM (0.43) | MMECPA1MGAMGAASI | |
| SCHEMBL6265890 | 0.86 | MGAM (0.50) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL2637637 | 0.83 | ALOX15 (0.40) | SLC1A3SLC1A2MGAMGAASI | |
| SCHEMBL8797367 | 0.82 | NAAA (0.42) | SLC1A3SLC1A2MMECPA1ALDH1A1 | |
| SCHEMBL1823767 | 0.82 | MGAM (0.46) | SLC1A3SLC1A2MGAMGAASI | |
| SCHEMBL4755497 | 0.82 | MGAM (0.46) | SLC1A3SLC1A2MGAMGAASI | |
| SCHEMBL7767241 | 0.80 | MGAM (0.44) | CPA1MGAMGAASIMGAM2 | |
| SCHEMBL4743296 | 0.80 | MME (0.51) | SLC1A3SLC1A2MMECPA1LAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546228-B2 | Modification of polymers containing an anhydride and uses thereof | ISP INVESTMENTS LLC (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150315307-A1 | MODIFICATION OF POLYMERS CONTAINING AN ANHYDRIDE AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2015-11-05 | — | — | US | disclosed |
| WO-2011141923-A2 | IMPROVED SYNTHESIS OF OPTICALLY PURE (S) - 3-CYANO-5-METHYL-HEXANOIC ACID ALKYL ESTER, AN INTERMEDIATE OF (S)- PREGABALIN | LUPIN LIMITED (IN) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141923-A2 | IMPROVED SYNTHESIS OF OPTICALLY PURE (S) - 3-CYANO-5-METHYL-HEXANOIC ACID ALKYL ESTER, AN INTERMEDIATE OF (S)- PREGABALIN | LUPIN LIMITED (IN) | 2011-11-17 | — | — | WO | disclosed |
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-0214639-B1 | HYDROXAMIC ACID BASED COLLAGENASE INHIBITORS | G.D. Searle & Co. (US) | 1990-06-13 | — | — | EP | disclosed |
| US-4743587-A | ANTIARTHRITIC AGENTS | G. D. SEARLE & CO. (US) | 1988-05-10 | — | — | US | disclosed |
| EP-0214639-A2 | Hydroxamic acid based collagenase inhibitors | G.D. Searle & Co. (US) | 1987-03-18 | — | — | EP | disclosed |
| US-4599361-A | ANTIARTHRITIC | G. D. SEARLE & CO. (US) | 1986-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | SLC1A3 4701/4885SLC1A2 4790/4885MME 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.